A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

K Sweet, L Hazlehurst, E Sahakian, J Powers… - Leukemia research, 2018 - Elsevier
Purpose Preclinical evidence indicates that the bone marrow microenvironment provides a
protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL …
被引用次数：55 相关文章

[引用][C] A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

K Sweet, L Hazlehurst, E Sahakian, J Powers… - Leukemia …, 2018 - cir.nii.ac.jp
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia
patients with molecular evidence of disease | CiNii Research CiNii 国立情報学研究所 学術情報 …
[HTML] nih.gov

[HTML][HTML] A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

K Sweet, L Hazlehurst, E Sahakian, J Powers… - Leukemia …, 2018 - ncbi.nlm.nih.gov
Purpose: Preclinical evidence indicates that the bone marrow microenvironment provides a
protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL …

A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.

K Sweet, L Hazlehurst, E Sahakian, J Powers… - Leukemia …, 2018 - europepmc.org
Purpose Preclinical evidence indicates that the bone marrow microenvironment provides a
protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL …

A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

K Sweet, L Hazlehurst, E Sahakian… - Leukemia …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose Preclinical evidence indicates that the bone marrow microenvironment provides a
protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL …